<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03465722</url>
  </required_header>
  <id_info>
    <org_study_id>BLU-285-1303</org_study_id>
    <nct_id>NCT03465722</nct_id>
  </id_info>
  <brief_title>(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST</brief_title>
  <official_title>An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blueprint Medicines Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, Phase 3 study in patients with locally advanced
      unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus
      regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of avapritinib based on progression-free survival (PFS) determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST), version 1.1</measure>
    <time_frame>24 Months</time_frame>
    <description>To demonstrate the efficacy of avapritinib based on progression-free survival (PFS) determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST), version 1.1 in patients with advanced GIST following 2 or 3 regimens of prior treatment with a tyrosine kinase inhibitor (TKI), including imatinib, compared to patients treated with regorafenib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) determined by central radiology assessment per mRECIST, version 1.1</measure>
    <time_frame>24 Months</time_frame>
    <description>To evaluate objective response rate (ORR) determined by central radiology assessment per mRECIST, version 1.1 in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib</measure>
    <time_frame>60 Months</time_frame>
    <description>To evaluate overall survival (OS) in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-C30) physical functioning score in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To evaluate the mean change from baseline to week 12 in European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-C30) physical functioning score in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC-QLQ-C30 pain score in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To evaluate the mean change from baseline to week 12 in EORTC-QLQ-C30 pain score in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC-QLQ-C30 role functioning score in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To evaluate the mean change from baseline to week 12 in EORTC-QLQ-C30 role functioning score in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC-QLQ-C30 appetite loss score in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To evaluate the mean change from baseline to week 12 in EORTC-QLQ-C30 appetite loss score in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>GIST</condition>
  <arm_group>
    <arm_group_label>avapritinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg PO QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>regorafinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>160 mg PO QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avapritinib</intervention_name>
    <description>Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.</description>
    <arm_group_label>avapritinib</arm_group_label>
    <other_name>BLU-285</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>regorafenib</intervention_name>
    <description>Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).</description>
    <arm_group_label>regorafinib</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are ≥ 18 years of age.

          2. Patients who have histologically confirmed metastatic or unresectable GIST.

          3. Patients who received imatinib and 1 or 2 other TKIs as prior treatment regimens.
             Patients who experienced intolerance to prior therapies must have objective disease
             progression prior to enrollment onto BLU-285-1303 study.

          4. Patients who have an Eastern Cooperative Oncology Group Performance Status (ECOG PS)
             of 0 to 2.

        Exclusion Criteria:

          1. Patients who have received prior treatment with avapritinib or regorafenib.

          2. Patients who have received more than 3 different prior TKI treatment regimens.

          3. Patients who are known to be both V-kit Hardy-Zuckerman 4 feline sarcoma viral
             oncogene homolog (KIT) and platelet-derived growth factor receptor alpha (PDGRFα) wild
             type.

          4. Patients who received any systemic anticancer therapy within 2 weeks before
             randomization.

          5. Patients with clinically significant cardiovascular disease, thromboembolic disease,
             or significant risk of bleeding.

          6. Patients who have a non-healing wound, ulcer, or bone fracture.

          7. Patients who have poor organ function as defined by laboratory parameters specified in
             the protocol.

          8. Patients who have received neutrophil growth factor support within 14 days of
             randomization.

          9. Patients who require therapy with a concomitant medication that is a strong inhibitor
             or strong inducer of CYP3A4.

         10. Patients who have had a major surgical procedure within 14 days of randomization.
             Patient has significant traumatic injury within 28 days before randomization.

         11. Patients who have a history of another primary malignancy that has been diagnosed or
             required therapy within 3 years before randomization.

         12. Patients who have a history of a seizure disorder requiring anti-seizure medication.

         13. Patients who have metastases to the brain.

         14. Patients who have a QT interval corrected using Fridericia's formula (QTcF) of &gt; 450
             msec.

         15. Women who are unwilling, if not postmenopausal or surgically sterile, to abstain from
             sexual intercourse or employ highly effective contraception from the time of
             randomization and for at least 30 days after the last dose of study drug. Men who are
             unwilling, if not surgically sterile, to abstain from sexual intercourse or employ
             highly effective contraception from the time of randomization and for at least 90 days
             after the last dose of study drug.

         16. Women who are pregnant.

         17. Women who are breastfeeding.

         18. Patients who have prior or ongoing clinically significant illness, medical condition,
             surgical history, physical finding, or laboratory abnormality as determined by the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Blueprint Medicines</last_name>
    <phone>617-714-6707</phone>
    <email>studydirector@blueprintmedicines.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Summit Cancer Centers</name>
      <address>
        <city>Post Falls</city>
        <state>Idaho</state>
        <zip>83854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Other Relapsed or Refractory Solid Tumors</keyword>
  <keyword>BLU-285</keyword>
  <keyword>BLU 285</keyword>
  <keyword>BLUE-285</keyword>
  <keyword>BLUE 285</keyword>
  <keyword>Avapritinib</keyword>
  <keyword>GIST imatinib relapse</keyword>
  <keyword>GIST gleevec relapse</keyword>
  <keyword>GIST KIT</keyword>
  <keyword>GIST relapse</keyword>
  <keyword>GIST refractory</keyword>
  <keyword>GIST imatinib intolerance</keyword>
  <keyword>GIST TKI treatment</keyword>
  <keyword>GIST tyrosine kinase inhibitor treatment</keyword>
  <keyword>GIST TKI</keyword>
  <keyword>GIST tyrosine kinase inhibitor</keyword>
  <keyword>Advanced GIST</keyword>
  <keyword>GIST mutations</keyword>
  <keyword>GIST treatments</keyword>
  <keyword>Blueprint GIST</keyword>
  <keyword>Relapsed GIST clinical trial</keyword>
  <keyword>Refractory GIST clinical trial</keyword>
  <keyword>KIT-mutant GIST</keyword>
  <keyword>cancer gist</keyword>
  <keyword>gastrointestinal stromal tumor</keyword>
  <keyword>gist cancer</keyword>
  <keyword>PDGFRA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

